GTC Biotherapeutics (fka GTCB)

[y3maxx]

“… net cash utilization of $21-25 million for 2006…includes projected fourth quarter 2006 cash receipts from our ongoing product supply commitments for Merrimack Pharmaceuticals…”

Question is Dew, will Merrimack make full disclosure of their two ph 2 results?

Haven't they already had two or three public presentations the last month or so, searching for new investors?
They could have had a positive response from new investors had they made public those results.


(IDIX seems more compelling at the moment.
Assured revenue by 2010, ample cash on hand w/a bazzilion shorts on record.)

tia